Healthcare sector earnings provide insight into company growth and development, with AstraZeneca leading in cancer medicines sales in Q4 2025. AstraZeneca saw 8.6% revenue growth to $58.7 billion, with after-tax profits reaching $10.2 billion. Edwards Lifesciences reported 13.3% sales growth in Q4, driven by TAVR momentum, while Zimmer Biomet’s revenue rose almost 11% to $2.2 billion, facing headwinds from tariffs.

Read more at Nasdaq: A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH